A Phase II Open-Label Study of Sorafenib Plus Fulvestrant As Salvage Therapy for Hormone receptor Positive Metastatic Breast Cancer Failing Prior Aromatase Inhibitor Treatment.

Trial Profile

A Phase II Open-Label Study of Sorafenib Plus Fulvestrant As Salvage Therapy for Hormone receptor Positive Metastatic Breast Cancer Failing Prior Aromatase Inhibitor Treatment.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs Sorafenib (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jul 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 06 Oct 2009 New source identified and integrated (Oregon Health and Science University Cancer Institute).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top